Secondary Antibiotic Resistance, Correlation between Genotypic and Phenotypic Methods and Treatment inHelicobacter pyloriInfected Patients: A Retrospective Study

被引:7
作者
Mascellino, Maria Teresa [1 ]
Oliva, Alessandra [1 ]
Miele, Maria Claudia [1 ]
De Angelis, Massimiliano [1 ]
Bruno, Giovanni [2 ]
Severi, Carola [2 ]
机构
[1] Sapienza Univ, Dept Publ Hlth & Infect Dis, I-00185 Rome, Italy
[2] Sapienza Univ, Dept Translat & Precis Med, I-00185 Rome, Italy
来源
ANTIBIOTICS-BASEL | 2020年 / 9卷 / 09期
关键词
Helicobacter pyloriinfection; molecular methods; E-test; multiresistance; patients therapy; HELICOBACTER-PYLORI INFECTION; CLARITHROMYCIN; SUSCEPTIBILITY; ERADICATION; METRONIDAZOLE; HELICODR; CHILDREN; THERAPY;
D O I
10.3390/antibiotics9090549
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The aim of this study was to evaluate the secondary resistance inHelicobacter pylori (Hp)infected patients who had failed a first-line therapy, and to compare the genotypic tests performed directly on gastric samples with phenotypic tests performed on culture media. The eradication rate of patients treated with bismuth quadruple therapy (BQT) is also evaluated. A total of 80 positive specimens were retrospectively examined. Antibiotic susceptibility testing ofHpstrains was performed by E-test, whereas a molecular commercially available method was used for detecting the mutations involved in clarithromycin and levofloxacin resistance. High resistance levels to metronidazole and clarithromycin (61.6% and 35%, respectively) and worrying resistance levels to levofloxacin (15%) were found phenotypically. Multiple resistance to two or three antibiotics was observed as well. The polymorphism A2143G on clarithromycin 23S rRNA gene was found in 34/80 (42.5%) isolates including 10 mixed infections (29%), whereas 28/80 (35%) strains were resistant phenotypically. Levofloxacin resistance corresponded to 30% by PCR and 15% by E-test (statistically significant,p< 0.05). The knowledge of clarithromycin and levofloxacin resistance is crucial to establish an appropriate therapy in different geographical areas. The genetic methods were superior to phenotypic techniques in the absence of live bacteria or for identifying mixed infections that may lead to a resistance underestimation. The BQT eradication rate was effective (90%).
引用
收藏
页码:1 / 11
页数:11
相关论文
共 46 条
[1]   Determination of minimum inhibitory concentrations [J].
Andrews, JM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 :5-16
[2]   Clinical and pathological importance of heterogeneity in vacA, the vacuolating cytotoxin gene of Helicobacter pylori [J].
Atherton, JC ;
Peek, RM ;
Tham, KT ;
Cover, TL ;
Blaser, MJ .
GASTROENTEROLOGY, 1997, 112 (01) :92-99
[3]  
Balakrishna JP, 2013, AM J CLIN PATHOL, V140, P101
[4]   Phenotypic and genotypic correlation as expressed in Helicobacter pylori resistance to clarithromycin and fluoroquinolones [J].
Binyamin, Dana ;
Pastukh, Nina ;
On, Avi ;
Paritsky, Maya ;
Peretz, Avi .
GUT PATHOGENS, 2017, 9
[5]   Antimicrobial resistance of Helicobacter pylori in Germany, 2015 to 2018 [J].
Bluemel, B. ;
Goelz, H. ;
Goldmann, B. ;
Grueger, J. ;
Hamel, H. ;
Loley, K. ;
Ludolph, T. ;
Meyer, J. ;
Miehlke, S. ;
Mohr, A. ;
Tuffers, K. ;
Usadel, H. ;
Wagner, S. ;
Wenzel, H. ;
Wiemer, L. ;
Vorreiter, J. ;
Eisele, B. ;
Hofreuter, D. ;
Glocker, E. -O. .
CLINICAL MICROBIOLOGY AND INFECTION, 2020, 26 (02) :235-239
[6]   Helicobacter pylori Primary Antibiotic Resistance in 2015 in Morocco: A Phenotypic and Genotypic Prospective and Multicenter Study [J].
Bouihat, Najat ;
Burucoa, Christophe ;
Benkirane, Ahmed ;
Seddik, Hassan ;
Sentissi, Sara ;
Al Bouzidi, Abderrahmane ;
Elouennas, Mustapha ;
Benouda, Amina .
MICROBIAL DRUG RESISTANCE, 2017, 23 (06) :727-732
[7]   Hypersecretory duodenal ulcer and Helicobacter pylori infection:: a four-year follow-up study [J].
Capurso, G ;
Martino, G ;
Grossi, C ;
Annibale, B ;
Delle Fave, G .
DIGESTIVE AND LIVER DISEASE, 2000, 32 (02) :119-124
[8]   Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment [J].
Chen, Qi ;
Long, Xiaohua ;
Ji, Yingjie ;
Liang, Xiao ;
Li, Dongping ;
Gao, Hong ;
Xu, Beili ;
Liu, Ming ;
Chen, Ying ;
Sun, Yunwei ;
Zhao, Yan ;
Xu, Gang ;
Song, Yanyan ;
Yu, Lou ;
Zhang, Wei ;
Liu, Wenzhong ;
Graham, David Y. ;
Lu, Hong .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2019, 49 (11) :1385-1394
[9]   Synthesis and in vitro selective anti-Helicobacter pylori activity of N-substituted-2-oxo-2H-1-benzopyran-3-carboxamides [J].
Chimenti, F ;
Bizzarri, B ;
Bolasco, A ;
Secci, D ;
Chimenti, P ;
Carradori, S ;
Granese, A ;
Rivanera, D ;
Lilli, D ;
Scaltrito, MM ;
Brenciaglia, MI .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2006, 41 (02) :208-212
[10]   Rifabutin and Furazolidone Could Be the Candidates of the Rescue Regimen for Antibiotic-Resistant H. pylori in Korea [J].
Choi, Youn I. ;
Jeong, Sang-Ho ;
Chung, Jun-Won ;
Park, Dong Kyun ;
Kim, Kyoung Oh ;
Kwon, Kwang An ;
Kim, Yoon Jae ;
So, Seol ;
Lee, Jeong Hoon ;
Jeong, Jin-Young ;
Lee, Sun-Mi .
CANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY, 2019, 2019